Ikena Oncology Completes Merger, Becomes ImageneBio, Inc.

An update from Ikena Oncology ( (IKNA) ) is now available.

On July 25, 2025, Ikena Oncology completed a merger with Inmagene, resulting in the formation of ImageneBio, Inc. This merger included a 1-for-12 reverse stock split and a name change to ImageneBio, Inc. The merger positions ImageneBio as a significant player in the biopharmaceutical industry, with a focus on developing therapies for immunological and inflammatory diseases. The company has divested its non-OX40 business to focus on its lead product candidate, IMG-007, which is in clinical development for atopic dermatitis and other potential indications. Post-merger, the company’s stock began trading under the new ticker symbol ‘IMA’ on the Nasdaq Capital Market.

The most recent analyst rating on (IKNA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ikena Oncology stock, see the IKNA Stock Forecast page.

Spark’s Take on IKNA Stock

According to Spark, TipRanks’ AI Analyst, IKNA is a Neutral.

Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.

To see Spark’s full report on IKNA stock, click here.

More about Ikena Oncology

ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immunological and inflammatory diseases. Their lead product candidate, IMG-007, is an anti-OX40 monoclonal antibody aimed at treating conditions such as atopic dermatitis and alopecia areata.

Average Trading Volume: 17,575

Technical Sentiment Signal: Sell

Find detailed analytics on IKNA stock on TipRanks’ Stock Analysis page.